Travere Therapeutics
TVTX
126 hedge funds and large institutions have $875M invested in Travere Therapeutics in 2016 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 51 increasing their positions, 36 reducing their positions, and 10 closing their positions.
406% more call options, than puts
Call options by funds: $35.1M | Put options by funds: $6.93M
150% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 10
42% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 36
23% more capital invested
Capital invested by funds: $710M → $875M (+$165M)
14% more funds holding
Funds holding: 111 → 126 (+15)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
+$15.4M |
| 2 |
SCM
Scopia Capital Management
New York
|
+$8.4M |
| 3 |
Millennium Management
New York
|
+$7.99M |
| 4 |
CCM
Consonance Capital Management
New York
|
+$7.33M |
| 5 |
KCM
Kingdon Capital Management
New York
|
+$7.23M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$21.8M |
| 2 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$19.8M |
| 3 |
PA
Perceptive Advisors
New York
|
-$15.9M |
| 4 |
PWAM
Park West Asset Management
San Francisco,
California
|
-$14.2M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$9.78M |
TVTX Hedge Fund Activity: Q3 2016 in Review
126 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Travere Therapeutics (TVTX) for Q3 2016, worth a combined $875M — up 23% from $710M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new TVTX positions and 10 closed out — a net gain of 15 holders — while 51 added to existing stakes and 36 trimmed.
The largest buyer was Broadfin Capital, adding an estimated $15.4M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $21.8M sold.
- 126 institutional investors held Travere Therapeutics (TVTX) as of Q3 2016, up from 111 in Q2 2016.
- Funds reported $875M of Travere Therapeutics stock for Q3 2016, up 23% quarter-over-quarter.
- 25 funds opened new Travere Therapeutics positions in Q3 2016 and 10 closed out, a net change of +15 holders.
- The largest Travere Therapeutics buyer in Q3 2016 was Broadfin Capital, an estimated $15.4M added.
- The largest Travere Therapeutics seller in Q3 2016 was EcoR1 Capital, an estimated $21.8M sold.
Based on aggregated 13F filings for Q3 2016.